(Q27692015)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295421%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Justin Stebbing

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295421%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

Daniel Krell

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295421%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Adam E Frampton

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295421%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Jonathan Krell

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295421%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Chiara Bardella

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295421%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

language of work or name

English

0 references

publication date

December 2013

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295421%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

volume

9

2 references

PubMed

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295421%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

issue

12

2 references

PubMed

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295421%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

page(s)

1923-1935

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295421%20AND%20SRC:MED&resulttype=core&format=json

Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity

9 June 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Role of NADP+-dependent isocitrate dehydrogenase (NADP+-ICDH) on cellular defence against oxidative injury by gamma-rays

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Silencing of cytosolic NADP(+)-dependent isocitrate dehydrogenase by small interfering RNA enhances the sensitivity of HeLa cells toward staurosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Small interfering RNA-mediated silencing of mitochondrial NADP+-dependent isocitrate dehydrogenase enhances the sensitivity of HeLa cells toward tumor necrosis factor-alpha and anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Insights from retinitis pigmentosa into the roles of isocitrate dehydrogenases in the Krebs cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Recurring mutations found by sequencing an acute myeloid leukemia genome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

IDH mutation status in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Expanding the spectrum of IDH1 mutations in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Knockdown of cytosolic NADP(+) -dependent isocitrate dehydrogenase enhances MPP(+) -induced oxidative injury in PC12 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Cancer-associated IDH mutations: biomarker and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

D-2-Hydroxyglutaric aciduria: unravelling the biochemical pathway and the genetic defect

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Mutations in the D-2-hydroxyglutarate dehydrogenase gene cause D-2-hydroxyglutaric aciduria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

An overview of L-2-hydroxyglutarate dehydrogenase gene (L2HGDH) variants: a genotype-phenotype study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

L-2-hydroxyglutaric aciduria and brain tumors in children with mutations in the L2HGDH gene: neuroimaging findings

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

L-2-hydroxyglutaric aciduria and brain malignant tumors: a predisposing condition?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

IDH2 mutations in patients with D-2-hydroxyglutaric aciduria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Progress in understanding 2-hydroxyglutaric acidurias

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Evidence for genetic heterogeneity in D-2-hydroxyglutaric aciduria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Expanding chemical biology of 2-oxoglutarate oxygenases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Structural studies on human 2-oxoglutarate dependent oxygenases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

(1)H NMR metabolomics identification of markers of hypoxia-induced metabolic shifts in a breast cancer model system

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Mitochondrial tumour suppressors: a genetic and biochemical update

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Hypoxia-inducible factors and the response to hypoxic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

The hypoxic response of tumors is dependent on their microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Genetic evidence for a tumor suppressor role of HIF-2alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Inborn and acquired metabolic defects in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

IDH mutation impairs histone demethylation and results in a block to cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Emerging roles of TET proteins and 5-hydroxymethylcytosines in active DNA demethylation and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Revisiting the TCA cycle: signaling to tumor formation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

The biology of cancer: metabolic reprogramming fuels cell growth and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

SDH5 mutations and familial paraganglioma: somewhere Warburg is smiling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

21 January 2018

SDH mutations in cancer

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Mitochondrial energy metabolism is markedly impaired by D-2-hydroxyglutaric acid in rat tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

NMDA receptor activation and respiratory chain complex V inhibition contribute to neurodegeneration in d-2-hydroxyglutaric aciduria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

ATP-citrate lyase links cellular metabolism to histone acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Autocrine glutamate signaling promotes glioma cell invasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Metformin and reduced risk of cancer in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

A pyruvate cycling pathway involving cytosolic NADP-dependent isocitrate dehydrogenase regulates glucose-stimulated insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Silencing of mitochondrial NADP+-dependent isocitrate dehydrogenase gene enhances selenite-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

D-2-hydroxyglutaric acid induces oxidative stress in cerebral cortex of young rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Monoclonal antibody specific for IDH1 R132H mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Interlaboratory comparison of IDH mutation detection.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Unraveling the glioma epigenome: from molecular mechanisms to novel biomarkers and therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143

An in vivo patient-derived model of endogenous IDH1-mutant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.143